260 related articles for article (PubMed ID: 16236433)
1. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
Thomas S; Reisman D
Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53.
Loging WT; Reisman D
Oncogene; 1999 Dec; 18(52):7608-15. PubMed ID: 10602522
[TBL] [Abstract][Full Text] [Related]
3. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways.
Kühnel F; Zender L; Wirth T; Schulte B; Trautwein C; Manns M; Kubicka S
Cancer Gene Ther; 2004 Jan; 11(1):28-40. PubMed ID: 14681724
[TBL] [Abstract][Full Text] [Related]
5. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
6. Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
Loging WT; Reisman D
Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):1011-6. PubMed ID: 10566557
[TBL] [Abstract][Full Text] [Related]
7. Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells.
Pratt MA; White D; Kushwaha N; Tibbo E; Niu MY
Apoptosis; 2007 Apr; 12(4):657-69. PubMed ID: 17252199
[TBL] [Abstract][Full Text] [Related]
8. p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription.
Innocente SA; Lee JM
FEBS Lett; 2005 Feb; 579(5):1001-7. PubMed ID: 15710382
[TBL] [Abstract][Full Text] [Related]
9. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
11. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.
Zalcenstein A; Stambolsky P; Weisz L; Müller M; Wallach D; Goncharov TM; Krammer PH; Rotter V; Oren M
Oncogene; 2003 Aug; 22(36):5667-76. PubMed ID: 12944915
[TBL] [Abstract][Full Text] [Related]
13. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.
Zastawny RL; Salvino R; Chen J; Benchimol S; Ling V
Oncogene; 1993 Jun; 8(6):1529-35. PubMed ID: 8502478
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein.
Lee Y; Chen Y; Chang LS; Johnson LF
Exp Cell Res; 1997 Aug; 234(2):270-6. PubMed ID: 9260894
[TBL] [Abstract][Full Text] [Related]
15. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
Inga A; Monti P; Fronza G; Darden T; Resnick MA
Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
[TBL] [Abstract][Full Text] [Related]
16. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis.
Liu J; Zhan M; Hannay JA; Das P; Bolshakov SV; Kotilingam D; Yu D; Lazar AF; Pollock RE; Lev D
Mol Cancer Res; 2006 Nov; 4(11):803-10. PubMed ID: 17077165
[TBL] [Abstract][Full Text] [Related]
17. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
[TBL] [Abstract][Full Text] [Related]
18. Wild-type p53 down-regulates transcription from oncogenic human papillomavirus promoters through the epithelial specific enhancer.
Desaintes C; Hallez S; Detremmerie O; Burny A
Oncogene; 1995 Jun; 10(11):2155-61. PubMed ID: 7784059
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid hormone-related protein gene expression in human squamous carcinoma cells is repressed by mutant isoforms of p53.
Foley J; Wysolmerski JJ; Broadus AE; Philbrick WM
Cancer Res; 1996 Sep; 56(17):4056-62. PubMed ID: 8752179
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional activities of mutant p53: when mutations are more than a loss.
Kim E; Deppert W
J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]